Equities analysts expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) to post earnings of ($0.46) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.50). Rhythm Pharmaceuticals posted earnings per share of ($0.41) in the same quarter last year, which would suggest a negative year over year growth rate of 12.2%. The company is expected to report its next earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($1.94) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.86). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.38) per share, with EPS estimates ranging from ($3.51) to ($1.75). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.06).

Several equities analysts have recently commented on RYTM shares. BidaskClub lowered Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. Needham & Company LLC set a $42.00 price target on Rhythm Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research lowered Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Morgan Stanley set a $38.00 price target on Rhythm Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, September 7th. Finally, Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research note on Friday, September 14th. They issued a “hold” rating and a $36.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $38.60.

In other Rhythm Pharmaceuticals news, insider Der Ploeg Leonardus H.T. Van sold 31,800 shares of the company’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $29.80, for a total transaction of $947,640.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Keith Michael Gottesdiener sold 16,500 shares of the company’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $30.08, for a total value of $496,320.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,300 shares of company stock worth $2,587,380. Corporate insiders own 4.93% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its stake in shares of Rhythm Pharmaceuticals by 15.8% in the 1st quarter. Northern Trust Corp now owns 90,548 shares of the company’s stock valued at $1,802,000 after purchasing an additional 12,367 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 7.1% in the 1st quarter. BlackRock Inc. now owns 385,802 shares of the company’s stock valued at $7,678,000 after purchasing an additional 25,731 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Rhythm Pharmaceuticals in the 1st quarter valued at $1,342,000. TD Asset Management Inc. bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter valued at $364,000. Finally, Alps Advisors Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 9.2% in the 2nd quarter. Alps Advisors Inc. now owns 39,952 shares of the company’s stock valued at $1,249,000 after purchasing an additional 3,359 shares during the last quarter. Institutional investors own 87.08% of the company’s stock.

Shares of Rhythm Pharmaceuticals stock opened at $29.35 on Monday. Rhythm Pharmaceuticals has a 52 week low of $16.80 and a 52 week high of $37.23. The firm has a market capitalization of $1.03 billion and a PE ratio of -10.37.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Featured Article: How is Preferred Stock Different from Common Stock?

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.